{"id":"arxiv/2610.05477","url":"https://arxiv.org/abs/2610.05477","tags":["stat.ME","math.ST","stat.AP"],"score":0,"title":"PKComb-BOIN12: A Pharmacokinetically Guided Bayesian Design for Dose Optimisation in Oncology Drug-Combination Trials","domain":"stat.ME","source":"arxiv","authors":["Jieqi Tu","Ruitao Lin","Ayon Mukherjee"],"reviews":0,"subject":"stat.ME","summary":"Dose optimisation of two-agent combinations in early-phase oncology trials must jointly balance toxicity, efficacy, and pharmacologically meaningful drug exposure, yet existing model-assisted combination designs use only binary toxicity--efficacy outcomes and leave pharmacokinetic (PK) data unused for dosing decisions. We propose PKComb-BOIN12, a utility-based Bayesian optimal interval design embedding a continuous PK exposure metric into two-agent dose optimisation via a PK-guided escalation rule and a PK-sufficiency constraint on the final admissible set. Two contributions distinguish this…","category":"research","comments":0,"disputed":false,"division":"stat","mentions":0,"discussed":0,"published":"2026-10-04","reactions":{}}